Emerald Advisers Inc. PA decreased its stake in Imperva Inc. (NYSE:IMPV) by 0.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 471,732 shares of the company’s stock after selling 1,039 shares during the period. Imperva comprises approximately 1.0% of Emerald Advisers Inc. PA’s holdings, making the stock its 27th largest position. Emerald Advisers Inc. PA owned about 1.46% of Imperva worth $20,289,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Bank of Montreal Can acquired a new position in Imperva during the second quarter valued at $107,000. Wellington Management Group LLP raised its position in Imperva by 2.2% in the first quarter. Wellington Management Group LLP now owns 450,415 shares of the company’s stock valued at $22,745,000 after buying an additional 9,620 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its position in Imperva by 3.1% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 697,284 shares of the company’s stock valued at $35,213,000 after buying an additional 21,266 shares in the last quarter. JPMorgan Chase & Co. raised its position in Imperva by 46.8% in the first quarter. JPMorgan Chase & Co. now owns 1,479,012 shares of the company’s stock valued at $74,688,000 after buying an additional 471,250 shares in the last quarter. Finally, Prudential Financial Inc. raised its position in Imperva by 102.4% in the first quarter. Prudential Financial Inc. now owns 6,991 shares of the company’s stock valued at $353,000 after buying an additional 3,537 shares in the last quarter. Hedge funds and other institutional investors own 93.26% of the company’s stock.

Institutional Ownership by Quarter for Imperva (NYSE:IMPV)

Imperva Inc. (NYSE:IMPV) traded down 0.41% during trading on Tuesday, hitting $53.56. The stock had a trading volume of 439,001 shares. Imperva Inc. has a 1-year low of $31.11 and a 1-year high of $77.99. The firm has a 50 day moving average price of $47.19 and a 200-day moving average price of $44.51. The firm’s market capitalization is $1.75 billion.

Imperva (NYSE:IMPV) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($0.23) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by $0.19. Imperva had a negative net margin of 23.75% and a negative return on equity of 25.68%. The business earned $57.87 million during the quarter, compared to the consensus estimate of $66.06 million. During the same period in the previous year, the business posted ($0.08) EPS. Imperva’s revenue was up 8.2% compared to the same quarter last year. On average, equities research analysts expect that Imperva Inc. will post ($0.80) EPS for the current year.

Several research analysts have weighed in on IMPV shares. Wunderlich started coverage on Imperva in a report on Tuesday, September 13th. They set a “hold” rating and a $50.00 target price on the stock. Buckingham Research lowered Imperva from a “buy” rating to a “neutral” rating in a report on Thursday, September 29th. Pacific Crest lowered Imperva from an “overweight” rating to a “sector weight” rating and reduced their target price for the stock from $47.00 to $30.00 in a report on Tuesday, August 30th. BTIG Research restated a “buy” rating and issued a $55.00 price target on shares of Imperva in a report on Tuesday, June 21st. Finally, JMP Securities restated an “outperform” rating and issued a $56.00 price target (up from $50.00) on shares of Imperva in a report on Sunday, September 25th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $53.33.

In other Imperva news, insider Amichai Shulman sold 3,085 shares of Imperva stock in a transaction that occurred on Wednesday, July 27th. The shares were sold at an average price of $46.28, for a total transaction of $142,773.80. Following the transaction, the insider now owns 93,380 shares of the company’s stock, valued at approximately $4,321,626.40. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Mark E. Kraynak sold 2,967 shares of Imperva stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $46.15, for a total transaction of $136,927.05. Following the transaction, the senior vice president now directly owns 2,968 shares in the company, valued at approximately $136,973.20. The disclosure for this sale can be found here. 2.20% of the stock is currently owned by corporate insiders.

Imperva Company Profile

Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company operates in the segment of development, marketing, sales, service and support of cyber-security solutions that protect business critical data and applications whether in the cloud or on premises.

5 Day Chart for NYSE:IMPV

Receive News & Stock Ratings for Imperva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva Inc. and related stocks with our FREE daily email newsletter.